San Francisco-based start-up Triomics has raised $15 million in new funding to further develop its artificial intelligence (AI) platform aimed at simplifying the process of matching cancer patients with the most suitable clinical trials and treatments. The platform uses large language models to analyze unstructured patient data and quickly identify key data points to facilitate the matching process. Triomics claims its AI-driven solution can achieve a 95% accuracy rate in matching patients to trials while significantly reducing the time required to review cases.
In addition to improving patient access to trials and treatments, Triomics’ platform has other applications such as automating manual processes for healthcare providers. The company’s focus on converting complex cancer data into actionable information to enhance patient care has garnered interest from oncologists, such as Anai Kothari from the Medical College of Wisconsin Cancer Center, who appreciate the potential impact of this technology on clinical practice.
Triomics attributes its success since launching in 2020 to its strategic approach of combining expertise in AI and clinical oncology. The company has expanded its platform through partnerships with hospital and healthcare providers and aims to onboard up to 15 institutions by the end of the year. Triomics plans to use the recently raised funds to continue recruiting talent and further enhance its platform to drive innovation in cancer care.
Investors, including Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, see the potential of Triomics’ platform to automate clinical trials and streamline cancer center workflows. Dev Khare of Lightspeed highlights the company’s use of generative AI and healthcare datasets to empower hospital staff in managing clinical trials efficiently. Jishnu Bhattacharjee of Nexus Venture Partners praises Triomics for its early success with oncology-specific language models and partnerships with leading cancer care and research centers.
In a field where speed and accuracy are crucial, Triomics’ AI platform offers a promising solution to the challenges of matching cancer patients with appropriate clinical trials and treatments. By leveraging cutting-edge technology and oncology expertise, the company aims to revolutionize cancer care delivery and improve patient outcomes. With a strong investor backing and a growing network of healthcare partners, Triomics is well positioned to make a significant impact on cancer care providers and patients in the US and beyond.
